Process Validation: Using Tolerance Intervals for Setting Process Validation Acceptance Criteria - - BioPharm International


Process Validation: Using Tolerance Intervals for Setting Process Validation Acceptance Criteria

BioPharm International
Volume 20, Issue 6

Figure 3
A flowchart that could be used in selecting an appropriate method is shown in Figure 3. The use of this flowchart is demonstrated in the example application that follows.


To demonstrate the approach shown in Figure 3, we present an example for a chromatography step used in purifying a recombinant protein.

Table 2. Distribution of data by scale
The full data set from this step consists of 76 observations distributed by scale (Table 2). EOR studies (1X OR bench) are performed at the upper and lower ranges of the OR for a given OP. ROB studies (3X OR bench) are performed at three times the upper and lower range of the OR.

Values for the OPs are unknown for the large-scale GMP and non-GMP runs, but known for the bench studies. Suppose we want to construct a tolerance interval to establish a VAC for a purity PP using only the three large-scale GMP runs. Equation (1) can be used to compute a tolerance interval that contains 99% of the population with 95% confidence using the three GMP values in the data set. From the data, the sample mean of the three observations is Y mean = 89.5, the standard deviation is S = 1.68, c = 3, r = 2, α = 0.05, and p = 0.99. This provides:

Z(p+1)/2 = Z(0.99+1)/2 = Z0.995 = 2.576


χ2 r,a = χ2 2,0.05 = 0.1026

so that the computed value of k 2 is

The resulting tolerance interval is the following:

89.5 – 13.1(1.68) = 67.4 (lower limit) to
89.5 + 13.1(1.68) = 112 (upper limit)

This is a relatively wide interval because of the large value for k 2 due to the small sample size. Thus, the use of bench-scale process characterization data is useful for shortening this interval to a more informative width.

Table 3. Regression of three operating parameters (OPs ) on a performance parameter (PP)
Table 3 reports a regression model for the PP based on a set of three OPs using the entire set of 76 data points. Note that this data set includes data from both the 1X and 3X ranges of the OPs, as well as the large-scale data. The OP values for the large-scale runs are taken as the setpoint values. The OPs have been coded to have value zero at setpoint conditions. A statistical test of equal means provides no evidence that the mean of the large-scale GMP runs differs from the other scales. Statistical tests of equal variance among the different groups of data fail to disclose any evidence of a difference in spread.

The root mean squared error (RMSE) in Table 3 is 1.64, which is relatively close to the standard deviation of the clinical runs (1.68). This suggests that combining the GMP data with the rest of the data set is reasonable and will provide a better estimate of the standard deviation. By combining the data, the value of r increases from 2 to 72 and the tolerance interval is shortened accordingly.

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here